A Novel Mouse Model for Genetic Validation of Therapeutic Targets in Breast Cancer
Abstract
Our proposal is focused on developing a versatile and generic technology platform that allows direct evaluation of the roles played by specific genes (and their products) in the genesis, progression and maintenance of breast cancer. We will construct genetically modified mice in which individual genes have been modified so as to incorporate a reversible switch. This will allow us to switch off (and on) individual target gene and determine what role that gene plays in mammary carcinoma. In effect, we can model the efficacy, specificity and side- effects of a drug designed to target that gene's function, either alone or in combination with existing therapies. We will test our proposed technology platform by investigating the roles of two pervasive proto-oncogenes, c- myc and E2f3, in breast oncogenesis. Both c-myc and E2f3 are pivotal determinants of mammary epithelial cell proliferation, differentiation, survival and tumor progression and excellent theoretical targets for breast cancer therapy. By blocking the functions of each of these genes, separately and together, we will for the first time evaluate their separate and combined roles in driving breast cancer progression, in the maintenance of established tumors, and as therapeutic targets.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2005
- Accession Number
- ADA439203
Entities
People
- Gerard I. Evan
Organizations
- University of California, San Francisco